Page 124 - 《中国药科大学学报》2026年第2期

250 学报 Journal of China Pharmaceutical University 2026, 57(2): 246 − 255 第 57 卷

A B 40

Sham
30
Infarct rate/% 20 **
MCAO/R **

Aspirin (10 mg/kg)
10
Indobufen (20 mg/kg)
0
MCAO/R Aspirin Indobufen
(10 mg/kg) (20 mg/kg)
C D Sham
MCAO/R
100 ## Aspirin (10 mg/kg)
* ** ## # Indobufen (40 mg/kg)
80 ** ** *
Escape latency/s 40 * ** * *
Sham MCAO/R 60 * ## #

20

0
Aspirin (10 mg/kg) Indobufen (20 mg/kg) Day 10 Day 11 Day 12 Day 13 Day 14
Visible platform Invisible platform
Days after MCAO/R

E 8 ** F 60 * **

Number of crosses 6 4 2 ## ** Time spent in quadrant IV/% 40 ##

20

0 0
Sham MCAO/R Aspirin Indobufen Sham MCAO/R Aspirin Indobufen
(10 mg/kg) (20 mg/kg) (10 mg/kg) (20 mg/kg)

G 2.0 H 70 MCAO/R
** 60 Aspirin (10 mg/kg)
**
1.5 ** ** 50 Indobufen (20 mg/kg)
Postural reflex 1.0 ** ** Asymmetric score/% 40 ** **

30
∆∆
0.5 ** 20 ** * **
** **
∆∆
10 ** **
0 0
Day 2 Day 5 Day 10 Day 15 Day 2 Day 5 Day 10 Day 15
Days after MCAO/R Days after MCAO/R
Figure 2 Post-treatment of indobufen promotes learning, memory and motor ability of MCAO/R rats ( x ± s, n=8)
A: Representative images of cerebral infarct area after cerebral ischemia 15 days after MCAO/R; B: Quantification of cerebral infarct area; C:
Representative swimming tracks of MWM; D: Escape latency to find the visible/non-visible platform; E: Number of crosses in the probe test in
quadrant IV; F: Time spent in quadrant IV. G,H: Postural reflex test and cylinder test
##
ΔΔ
#
*P < 0.05, **P < 0.01 vs model group; P < 0.05, P < 0.01 vs sham group; P< 0.01 vs aspirin group